Abstracts tagged "osteoporosis and systemic lupus erythematosus (SLE)"

Abstract Number: 2327 • 2018 ACR/ARHP Annual Meeting
To Screen or Not to Screen?Dexa Ordering Patterns in SLE Patients Who Take Systemic Glucocorticoids
Sara Baig¹, Smarika Sapkota², Anna K. Shmagel³, Parastoo Fazeli⁴, Jeremiah Menk¹ and Ann Marie O'Connell⁵, ¹University of Minnesota, Minneapolis, MN, ²Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, ³Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ⁴Rheumatology, University of Minnesota, Minneapolis, MN, ⁵University of Minnesota, MInneapolis, MN
Background/Purpose: High doses of glucocorticoids (GC) are often used in the treatment of Systemic Lupus Erythematous (SLE), however, studies suggest that SLE patients do not…
Abstract Number: 2639 • 2018 ACR/ARHP Annual Meeting
Bone Mineral Density Is Not Associated with Osteoporotic Fractures in Premenopausal Women and Men < 50 Years Old with Systemic Lupus Erythematosus
Tracy Driver¹, Maureen A. McMahon², Betty Tsao³ and Jennifer M. Grossman⁴, ¹Medicine, Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²UCLA David Geffen School of Medicine, Los Angeles, CA, ³Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Osteoporosis is common in patients with systemic lupus erythematosus (SLE). Guidelines for the treatment and prevention of glucocorticoid induced osteoporosis (GIOP) are detailed for…
Abstract Number: 738 • 2016 ACR/ARHP Annual Meeting
Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus
Kazumasa Ohmura, Masaru Kato, Toshiyuki Watanabe, Ryo Hisada, Masatoshi Kanda, Sanae Shimamura, Ikuma Nakagawa, Yuka Shimizu, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Premature atherosclerosis is one of the major complications of systemic lupus erythematosus (SLE). Preventing atherosclerosis is a key objective while monitoring patients with SLE.…
Abstract Number: 1790 • 2016 ACR/ARHP Annual Meeting
Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³, Jiandong Su⁴ and The Systemic Lupus International Collaborating Clinics (SLICC) Group, ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The annual accrual of comorbidities in patients with SLE is not well described. We report the annual occurrence of these features in an inception…
Abstract Number: 1796 • 2016 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mario García-Carrasco^1,2, Pamela Soto-Santillan³, Samanda Adriana Rojas villarraga⁴, Nicolás Molano-González⁵ and Claudia Mendoza Pinto⁶, ¹Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Inmunología y Reumatología, Universidad Autónoma de Puebla, Puebla, Mexico, ³Internal Medicine, Systemic Autoimmune Diseases Research Unit, IMSS, Puebla, México, Puebla, Mexico, ⁴Novartis de Colombia, Bogota, Colombia, ⁵Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogota, Colombia, ⁶Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR, IMSS, Puebla, Mexico
Background/Purpose: Observational studies have indicated a high but heterogeneous prevalence of low bone mineral density (BMD) and vertebral fractures (FV) in patients with systemic lupus…
Abstract Number: 1833 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis
Maeve Gamble¹ and Janet E. Pope², ¹Medicine, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Osteoporosis (OP) and avascular necrosis (AVN) are well-recognized musculoskeletal complications of systemic lupus erythematosus (SLE) and cause morbidity. Steroid therapy and the underlying disease…
Abstract Number: 235 • 2014 ACR/ARHP Annual Meeting
Lower P1NP Serum Levels: a Predictive Marker of Bone Loss after One-Year Follow-up in premenopausal SLE Patients
Luciana Seguro¹, Caio B. Casella¹, Valéria Caparbo¹, Ricardo M. Oliveira², Alessandra C Bonfa¹, Eloisa Bonfa¹ and Rosa M R Pereira¹, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²RDO Diagnosticos Medicos, São Paulo, Brazil
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with high risk of low bone mass/fractures but this risk is still controversial in premenopausal women. Our aim…
Abstract Number: 1218 • 2013 ACR/ARHP Annual Meeting
Incidence Of and Risk Factors For Clinical Fractures In Patients With Systemic Lupus Erythematosus and Matched Controls: A Population-Based Study In The United Kingdom
Irene Bultink¹, Nicholas Harvey², Arief Lalmohamed^3,4, Cyrus Cooper⁵, Willem Lems⁶, Tjeerd Van Staa^2,3,7 and Frank de Vries^3,4,8,9, ¹Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ³Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands, ⁴Clinical Pharmacy, University Medical Center Utrecht, Utrecht, Netherlands, ⁵NDORMS; MRC Lifecourse Epidemiology Unit, University of Oxford; Southampton General Hospital, Southampton, United Kingdom, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁷Medicine and Helathcare Products Regulatory Agency, Clinical Practice Research Datalink, London, United Kingdom, ⁸Care and Public Health Research Institute, Maastricht, Netherlands, ⁹Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, Netherlands
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with an increased risk of low bone mineral density and fractures. However, data on absolute fracture risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].